RXN
Undervalued by 7.1% based on the discounted cash flow analysis.
Market cap | $11.44 Billion |
---|---|
Enterprise Value | $12.30 Billion |
Dividend Yield | $11.571 (0%) |
Earnings per Share | $1.45 |
Beta | 1.38 |
Outstanding Shares | 121,783,000 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | 44.81 |
---|---|
PEG | -421.58 |
Price to Sales | 4.06 |
Price to Book Ratio | 5.9 |
Enterprise Value to Revenue | 6.21 |
Enterprise Value to EBIT | 38.18 |
Enterprise Value to Net Income | 79 |
Total Debt to Enterprise | 0.1 |
Debt to Equity | 0.86 |
No data
No data